The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Samsung Bioepis’ bevacizumab biosimilar for the treatment of multiple types of cancer.
Samsung Bioepis said the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the company’s bevacizumab biosimilar (Aybintio).
The drug, which references Genentech’s Avastin, would be used for the treatment of metastatic carcinoma of the colon or rectum; metastatic breast cancer; non—small cell lung cancer; advanced or metastatic renal cell cancer; epithelial ovarian, fallopian tube, and primary peritoneal cancer; and cervical cancer.
The positive CHMP opinion will be reviewed by the European Commission, which will decide on the marketing approval for Aybintio.
“Once approved, Aybintio will be a valuable treatment option for different types of cancers, potentially helping many patients across Europe,” said Hee Kyung Kim, senior vice president of clinical science and regulatory affairs at Samsung Bioepis, in a statement.
CHMP gave a positive opinion following a review of pharmacokinetic and pharmacodynamic data demonstrating that Aybintio was highly similar to the reference product and had no clinically meaningful differences.
In the United States, Samsung Bioepis submitted a biologics license application for Aybintio in 2019 and the biosimilar candidate remains under review by the FDA.
Samsung Bioepis Pipeline
The company, based in Incheon, Republic of Korea, has 4 other biosimilars approved in Europe: Eticovo, an etanercept biosimilar; Renflexis, infliximab; Hadlima, adalimumab; and Ontruzant, trastuzumab. All 4 of those products are also approved in the United States, Republic of Korea, and Australia.
In 2019, Ontruzant became the first biosimilar to be prequalified by the World Health Organization (WHO). The WHO designation helps to guide many low- and middle-income countries in selecting medicines for use and may encourage biosimilar use, which could drive down drug prices.
Samsung Bioepis is also developing 4 other biosimilars, with Aybintio being the furthest along and the only one in the filing stage.
Both their ranibizumab (SB11) and eculizumab (SB12) biosimilars have completed phase 3 clinical trials. Their biosimilar aflibercept is currently in preclinical trials.
Commercialization Deals
In November 2019, Samsung Bioepis announced that it would enter into a commercialization agreement with Biogen for its ranibizumab and aflibercept biosimilars. The agreement woud cover marketing in the United States, Canada, Europe, Japan, and Australia.
The deal also allowed Biogen to receive commercialization rights for 3 anti—tumor necrosis factor agents in China in exchange for sales royalties.
In 2013, Samsung Bioepis entered into a development and commercialization agreement with Merck for a follow-on insulin glargine product, but patent infringement litigations from reference product developer Sanofi forced the companies to terminate the agreement in 2018.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.